Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-07-11
2006-07-11
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C514S002600, C514S008100
Reexamination Certificate
active
07074408
ABSTRACT:
The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.
REFERENCES:
patent: 5731288 (1998-03-01), Markland et al.
patent: 5814609 (1998-09-01), Markland et al.
patent: 5830742 (1998-11-01), Black et al.
patent: 5922546 (1999-07-01), Mayer et al.
patent: 5935578 (1999-08-01), Alves et al.
patent: 5935792 (1999-08-01), Rubin et al.
patent: 6013466 (2000-01-01), Black et al.
patent: 6140098 (2000-10-01), Balasubramanian et al.
patent: 6177475 (2001-01-01), Tatarintsev et al.
patent: 6190876 (2001-02-01), Rubin et al.
patent: 6255064 (2001-07-01), Tindal et al.
patent: 6265199 (2001-07-01), Sheppard et al.
patent: 2002/0001840 (2002-01-01), Lopez-Otin et al.
patent: WO9907856 (1999-02-01), None
patent: WO 99/23228 (1999-05-01), None
patent: WO 99/36549 (1999-07-01), None
patent: WO 99/41388 (1999-08-01), None
patent: WO 00/43525 (2000-07-01), None
patent: WO0043493 (2000-07-01), None
patent: WO0174857 (2001-10-01), None
Fogarty M, Learning from Angiogenesis Trial Failures. The Scientist 16(6):33, Mar. 2002.
Attwood TK. Genomics. The Babel of bioinformatics. Science. 290(5491):471-473, 2000.
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol. 18(1):34-9, 2000.
Ngo J.T, Marks J. Karplus M., Computational complexity, protein structure prediction, and the Levinthal paradox in The Protein Folding Problem, ch. 14, pp. 435-508, Birkhauser, 1994.
Fan et al Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci. 16(2):57-66, 1995.
Wallace RW. Media hype and drug discovery. Durg Discovery Today 10:433-434, 1998.
Zhou et al Molecular cloning and functional expression of contortrostatin, a homodimeric disintegrin from southern copperhead snake venom. Arch Biochem Biophys. Mar. 15, 2000;375(2):278-88.
Lu et al Preferential antagonism of the interactions of the integrin alpha IIb beta 3 with immobilized glycoprotein ligands by snake-venom RGD (Arg-Gly-Asp) proteins. . . . Biochem J. Dec. 15, 1994;304 ( Pt 3):929-36.
Juliano et al. Disintegrin interaction with alpha V beta 3 integrin on human umbilical vein endothelial cells: expression of ligand induced binding site on beta 3 subunit. Exp Cell Res. May 25, 1996;225(1):132-42.
Kuntz ID. Structure-based strategies for drug design and discovery. Science. Aug. 21, 1992;257(5073):1078-82.
Miller et al Ligand binding to proteins: the binding landscape model. Protein Sci. Oct. 1997;6(10):2166-79.
Nath D et al. “Interaction of metargidin (ADAM-15) with αvβ3and α5β1integrins on different haemopoietic cells,”J. Cell Science112:579-587, 1999.
Yeh CH et al. “Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin αvβ3antagonist and inducing apoptosis,”Blood92(9):3268-3276, Nov. 1, 1998.
Zhang X-P et al. “Specific Interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin αvβ3,”J. Biological Chem.273(13):7345-7350, Mar. 27, 1998.
Hooft van Huijsvuijen, “ADAM 20 and 21; two novel human testis-specific membrane metalloproteases with similarity to fertilin-α,”Gene206(2):273-282, 1998.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP), GenBank Accession No. AA758110, Dec. 1998.
Schluesener HJ, “The disintegrin domain of ADAM 8 enhances protection against rata experimental autoimmune encephalomyelitis, neuritis and uveitis by a polyvalent autoantigen vaccine,”.Neuroimmunology87 (1-2):197-202, Jul. 1998.
Sheu J-R, et al., “Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp—containing peptide and anti-alphavbeta3 integrin monoclonal antibody,”BBA-General Subjects, Elsevier Science Publishers, NL, 1336(3):445-454, Oct. 1997.
Tselepi VH, et al., “An RGD to LDV Motif Conversion within the Disintegrin Kistrin Generates an Integrin Antagonist That Retains Potency but Exhibits Altered Receptor Specificity,”J. Biological Chem272(34):21341-21348, Aug. 1997.
Westkamp G, et al., “MDC9, a Widely Expressed Cellular Disintegrin Containing Cytoplasmic SH3 Ligand Domains,”J. Cell Biol.132(4):717-726, Feb. 1996.
Wolfsberg TG, et al., “ADAM, a Novel Family of Membrane Proteins ContainingA DisintegrinAndMettaloprotease Domain: Multipotential Functions in Cell—Cell and Cell-Matrix Interactions,”J. Cell Biol.131(2):275-278, Oct. 1995.
Xu R, et al., “Molecular Cloning and Mapping of a Novel ADAM Gene(ADAM29) to Human Chromosome 4,”Genomics, 62:537-539, 1999.
Black Roy A.
Cerretti Douglas P.
Fanslow, III William C.
Poindexter Kurt M.
Chan Christina
Haddad Maher
Immunex Corporation
Smith Julie K.
Sprunger Suzanne A.
LandOfFree
Use of integrin antagonists to inhibit angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of integrin antagonists to inhibit angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of integrin antagonists to inhibit angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3584368